dabigatran has been researched along with arginine in 38 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (arginine) | Trials (arginine) | Recent Studies (post-2010) (arginine) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 46,388 | 1,688 | 11,176 |
| Protein | Taxonomy | dabigatran (IC50) | arginine (IC50) |
|---|---|---|---|
| Cationic amino acid transporter 3 | Homo sapiens (human) | 283 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.26) | 29.6817 |
| 2010's | 32 (84.21) | 24.3611 |
| 2020's | 4 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Büller, HR; Di Nisio, M; Middeldorp, S | 1 |
| Chevalier, A; Nutescu, EA; Shapiro, NL | 1 |
| Jiang, X; Wong, PC | 1 |
| Ansell, JE; Lee, CJ | 1 |
| Ageno, W; Streif, W | 1 |
| Bark, N; Blombäck, M; He, S; Wallèn, H | 1 |
| Fritsma, GA | 1 |
| Azuma, S; Lum, CJ | 1 |
| Alban, S; Birschmann, I; Busse, J; Dittrich, M; Eller, T; Flieder, T; Knabbe, C | 1 |
| Boyle, ME; Fisher, S; Ishimoto, J; Kiser, TH; Lind, SE; Trujillo, TC | 1 |
| Carrieri, C; Colucci, M; Incampo, F; Semeraro, N | 1 |
| Kadauke, S; Khor, B; Van Cott, EM | 1 |
| Ansell, J; Bakhru, S; Costin, J; Laulicht, B; Steiner, S | 1 |
| Li, M; Ren, Y | 1 |
| Cuker, A; Siegal, D | 1 |
| Agewall, S; Atar, D; Drexel, H; Husted, SE; Kaski, JC; Kjeldsen, K; Koller, L; Lewis, BS; Lip, GYH; Morais, J; Niessner, A; Storey, RF; Tamargo, J; Torp-Pedersen, C; Verheugt, FWA; Wassmann, S | 1 |
| Fujimori, Y; Katagiri, H; Murata, M; Ohira, K; Shimizu, N; Wakui, M | 1 |
| Ansell, JE | 1 |
| Fanikos, J; Smythe, MA; Trujillo, T | 1 |
| Hussain, SS; Mukherjee, D; Tyroch, AH | 1 |
| Arachchillage, DR; Baglin, T; Besser, M; Maclean, R; van Veen, JJ | 1 |
| Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI | 1 |
| Fredenburgh, JC; Leslie, BA; Stafford, AR; Weitz, JI; Yeh, CH | 1 |
| Antman, EM; Giugliano, RP; Ruff, CT | 1 |
| Fanikos, J; Huisman, MV | 2 |
| Levy, JH | 1 |
| Bhagirath, VC; Eikelboom, JW; Monagle, S; Ng, KH | 1 |
| Desborough, MJ; Shapiro, S; Zhang, XY | 1 |
| Gkiatas, I; Korompilias, AV; Kostas-Agnantis, I; Papadopoulos, DV; Tsantes, AG; Ziara, P | 1 |
| Fischer, AM; Godier, A; Martin, AC; Mauge, L; Smadja, DM | 1 |
| Gheysens, O; Goffin, KE; Hoylaerts, MF; Jacquemin, M; Liesenborghs, L; Peerlinck, K; Peetermans, M; Peetermans, WE; Vanassche, T; Verhaegen, J; Verhamme, P; Wijngaerden, EV | 1 |
| Cornelius, CC; Cripps, MW; Gales, PE; Nakonezny, PA; Vazquez, N; Wey, JC | 1 |
| Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI | 1 |
| Bari, N; Ho, JPK; Riffat, F | 1 |
| Ansell, J; Bakhru, S; Freedman, D; Laulicht, BE; Tracey, G; Villano, S | 1 |
| Fu, G; Liu, Z; Wang, Y; Yin, L; Zhang, K | 1 |
| Beyer-Westendorf, J; Brückner, L; Pietsch, J; Tiebel, O | 1 |
18 review(s) available for dabigatran and arginine
| Article | Year |
|---|---|
New anticoagulant agents: direct thrombin inhibitors.
Topics: Anticoagulants; Arginine; Atrial Fibrillation; Benzimidazoles; Dabigatran; Fibrinolytic Agents; Half-Life; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Pyridines; Recombinant Proteins; Stroke; Sulfonamides; Thrombin | 2008 |
Direct thrombin inhibitors.
Topics: Anticoagulants; Antithrombins; Arginine; Benzimidazoles; Dabigatran; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Pyridines; Recombinant Proteins; Sulfonamides; Thrombin; Venous Thromboembolism | 2011 |
Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children.
Topics: Adolescent; Anticoagulants; Arginine; Benzimidazoles; beta-Alanine; Child; Child, Preschool; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fondaparinux; Hirudins; Humans; Infant; Infant, Newborn; Morpholines; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Risk Factors; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Reversal agents in development for the new oral anticoagulants.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Piperazines; Recombinant Proteins; Thromboembolism | 2014 |
Monitoring and reversal of direct oral anticoagulants.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Partial Thromboplastin Time; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombin Time | 2015 |
Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Arginine; Blood Coagulation Disorders; Blood Coagulation Factors; Coagulants; Combined Modality Therapy; Dabigatran; Drugs, Investigational; Enoxaparin; Factor Xa; Fibrinolytic Agents; Humans; Piperazines; Practice Guidelines as Topic; Recombinant Proteins; Vitamin K | 2016 |
Reversal agents for use with direct and indirect anticoagulants.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Recombinant Proteins | 2016 |
Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs).
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antifibrinolytic Agents; Arginine; Blood Coagulation; Blood Coagulation Factors; Cardiovascular Diseases; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Models, Molecular; Piperazines; Recombinant Proteins | 2017 |
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Atrial Fibrillation; Congresses as Topic; Dabigatran; Drug Monitoring; Factor Xa; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Piperazines; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Thrombin Time; Venous Thromboembolism | 2016 |
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antithrombins; Arginine; Blood Coagulation Factors; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Plasma; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles | 2016 |
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.
Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Clinical Protocols; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban | 2016 |
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Dabigatran; Deprescriptions; Emergencies; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Piperazines; Prothrombin Time; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative | 2016 |
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Clinical Protocols; Dabigatran; Emergency Treatment; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Patient Selection; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative; Thiazoles | 2016 |
Clinical implications of reversal agents for direct oral anticoagulants.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
Reversal of direct oral anticoagulants.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Coagulants; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Partial Thromboplastin Time; Piperazines; Prothrombin Time; Recombinant Proteins; Thrombin Time | 2017 |
The role of new oral anticoagulants in orthopaedics: an update of recent evidence.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Tests; Dabigatran; Factor Xa; Hemorrhage; Humans; Orthopedic Procedures; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism | 2017 |
[State of the art: Direct oral anticoagulants and transfusion].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Blood Transfusion; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thrombophilia | 2017 |
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2019 |
2 trial(s) available for dabigatran and arginine
| Article | Year |
|---|---|
Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Arginine; Bacteremia; Belgium; Blood Coagulation; Coagulase; Dabigatran; Enoxaparin; Feasibility Studies; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Partial Thromboplastin Time; Pilot Projects; Pipecolic Acids; Prospective Studies; Staphylococcal Infections; Staphylococcus aureus; Sulfonamides; Thrombin; Thrombosis; Time Factors; Treatment Outcome | 2018 |
Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Arginine; Dabigatran; Healthy Volunteers; Humans; Middle Aged; Piperazines; Pyrazoles; Pyridones; Rivaroxaban | 2022 |
18 other study(ies) available for dabigatran and arginine
| Article | Year |
|---|---|
Direct thrombin inhibitors.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Arginine; Benzimidazoles; Blood Coagulation; Dabigatran; Heart Diseases; Heparin; Humans; Pipecolic Acids; Prodrugs; Pyridines; Sulfonamides; Thrombin; Thromboembolism; Thrombosis; Venous Thrombosis | 2005 |
Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Topics: Adenosine Diphosphate; Anticoagulants; Arginine; Azetidines; Benzimidazoles; Collagen; Dabigatran; Dose-Response Relationship, Drug; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Factor XIa; Humans; Morpholines; Pipecolic Acids; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Thromboplastin; Time Factors | 2010 |
In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban.
Topics: Aged; Anticoagulants; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Female; Hemostasis; Humans; Middle Aged; Pipecolic Acids; Sulfonamides; Treatment Outcome | 2013 |
Monitoring the direct thrombin inhibitors.
Topics: Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides | 2013 |
A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation.
Topics: Aged, 80 and over; Anticoagulants; Arginine; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Glomerular Filtration Rate; Hawaii; Humans; Male; Morpholines; Pipecolic Acids; Retrospective Studies; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2013 |
Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests.
Topics: Anticoagulants; Arginine; Artifacts; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Fondaparinux; Humans; Morpholines; Pipecolic Acids; Platelet Function Tests; Point-of-Care Systems; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombelastography; Whole Blood Coagulation Time | 2014 |
Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
Topics: Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Heparin; Hirudins; Humans; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time; Thromboplastin | 2014 |
The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
Topics: Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Carboxypeptidase B2; Dabigatran; Fibrinolysis; Humans; Pipecolic Acids; Protein C; Sulfonamides; Thrombin; Thrombomodulin | 2014 |
Activated protein C resistance testing for factor V Leiden.
Topics: Activated Protein C Resistance; Adult; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Biological Assay; Blood Coagulation Tests; Child; Dabigatran; Factor V; Factor Xa; False Positive Reactions; Female; Hirudins; Humans; Lupus Coagulation Inhibitor; Morpholines; Peptide Fragments; Pipecolic Acids; Pregnancy; Protein C; Recombinant Proteins; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2014 |
Synthesis and Biological Evaluation of Some New 2,5-Substituted 1-Ethyl-1H-benzoimidazole Fluorinated Derivatives as Direct Thrombin Inhibitors.
Topics: Antithrombins; Arginine; Benzimidazoles; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Design; Humans; Hydrocarbons, Fluorinated; Molecular Docking Simulation; Molecular Structure; Pipecolic Acids; Structure-Activity Relationship; Sulfonamides | 2015 |
Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharm
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Arginine; Consensus; Dabigatran; Evidence-Based Medicine; Factor Xa; Forecasting; Hemorrhage; Humans; Piperazines; Recombinant Proteins; Risk Factors; Thrombosis; Vitamin K | 2017 |
Evaluation of anticoagulant effects of direct thrombin inhibitors, dabigatran and argatroban, based on the Lineweaver-Burk plot applied to the Clauss assay.
Topics: Antithrombins; Arginine; Blood Coagulation; Dabigatran; Humans; Kinetics; Pipecolic Acids; Sulfonamides | 2016 |
Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Neoplasms; Pipecolic Acids; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Sulfonamides; Venous Thrombosis | 2016 |
Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function.
Topics: Allosteric Regulation; Antithrombins; Arginine; Binding Sites; Biocatalysis; Blood Coagulation; Catalytic Domain; Dabigatran; Fibrin; Fibrinogen; Humans; Pipecolic Acids; Protein Binding; Substrate Specificity; Sulfonamides; Surface Plasmon Resonance; Thrombin | 2016 |
In vitro effects of a kaolin-coated hemostatic dressing on anticoagulated blood.
Topics: Adult; Anticoagulants; Antithrombins; Arginine; Bandages; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Hemostatics; Heparin; Humans; Kaolin; Pipecolic Acids; Platelet Aggregation Inhibitors; Prospective Studies; Rivaroxaban; Sulfonamides; Viscoelastic Substances; Vitamin K | 2018 |
Management of epistaxis in patients on novel oral anticoagulation therapy.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Awareness; Dabigatran; Epistaxis; Factor Xa; Factor Xa Inhibitors; First Aid; Humans; Male; Piperazines; Prevalence; Recombinant Proteins; Rivaroxaban; Severity of Illness Index | 2020 |
Dabigatran Use after Argatroban for Heparin-induced Thrombocytopenia with Thrombosis: A Case Series and Literature Review.
Topics: Aged; Anticoagulants; Antithrombins; Arginine; Dabigatran; Drug Therapy, Combination; Fatal Outcome; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Male; Middle Aged; Pipecolic Acids; Platelet Count; Sulfonamides; Thrombocytopenia; Venous Thrombosis | 2022 |
Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC-MS/MS.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arginine; Chromatography, High Pressure Liquid; Dabigatran; Humans; Pipecolic Acids; Pyridones; Rivaroxaban; Sulfonamides; Tandem Mass Spectrometry; Thrombin | 2022 |